drugset / Trial / NCT01077401
Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study
Phase 2
Completed
152 enrolled
Johns Hopkins University
Juvenile Diabetes Research Foundation · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to investigate the safety, tolerability, bioactivity, and dose response of two different dosages (0.5 mg and 2.0 mg) of ranibizumab (RBZ) in patients with diabetic macular edema (DME).
Timeline
- Start
- 2010-02
- Primary completion
- 2012-03
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 2 mg | Intravitreal |